MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Country |
 USA |
IPO year |
2013 |
Industry |
Biotechnology |
Stock Exchange |
NYSESPB |
Shares |
454 M |
Market Cap[1] |
$ 57.3 B |
EBITDA (LTM) |
$ 487 M |
P/E (LTM) |
20.37 |
P/S (LTM) |
6.02 |
EPS (LTM) |
6.16 |
Zoetis is a global leader in animal health and veterinary medicine, providing a wide range of products and services to improve animal health, including medicines, vaccines, diagnostic tests, and animal health management programs. The company was created in 2013 after being spun off from Pfizer Inc., and is headquartered in New Jersey, USA.
Zoetis works with farmers, veterinarians, and other professionals in the livestock and animal health industries around the world. The company is committed to innovation and developing new products and services to improve animal health and provide more effective animal health management. Zoetis is also actively involved in social responsibility, supporting various charitable organizations and programs.
Today, Zoetis has a presence in over 100 countries and serves millions of animals. The company is constantly striving to improve its products and services to meet the needs of its customers and partners.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Arbutus Biopharma Corporation
ABUS
|
$ 4.78 | -0.31 % | $ 793 M | Nasdaq Global Select Market |  Canada |
 |
Aclaris Therapeutics
ACRS
|
$ 3.03 | -0.49 % | $ 234 M | Nasdaq Global Select Market | USA |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | USA |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Aptorum Group Limited
APM
|
$ 1.15 | -1.71 % | $ 6.27 M | Nasdaq Global Select Market |  China |
 |
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market |  Britain |
 |
Ascendis Pharma A/S
ASND
|
$ 209.39 | -1.61 % | $ 5 B | Nasdaq Global Select Market |  Danmark |
 |
Aptevo Therapeutics
APVO
|
$ 0.6 | -35.8 % | $ 166 K | Nasdaq Capital Market | USA |
 |
Alterity Therapeutics Limited
ATHE
|
$ 3.12 | 0.81 % | $ 7.51 B | Nasdaq Capital Market |  Australia |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market |  France |
 |
BioVie
BIVI
|
$ 1.2 | -5.51 % | $ 1.77 M | Nasdaq Capital Market | USA |
 |
Athersys
ATHX
|
- | 3.77 % | $ 22.4 M | Nasdaq Capital Market | USA |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | USA |
 |
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | USA |
 |
AVROBIO
AVRO
|
- | 1083.1 % | $ 745 M | Nasdaq Global Select Market | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 0.22 | 24.46 % | $ 479 M | NYSE American |  Israel |
 |
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
- | -15.15 % | $ 60.3 M | Nasdaq Global Select Market | Britain |
 |
BioDelivery Sciences International
BDSI
|
- | -4.8 % | $ 255 M | Nasdaq Global Select Market | USA |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
BioNTech SE
BNTX
|
$ 94.72 | -0.33 % | $ 27.2 B | Nasdaq Global Select Market | Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 27.09 | 1.04 % | $ 1.31 B | Nasdaq Global Select Market | USA |
 |
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market |  Cayman-islands |
 |
Anika Therapeutics
ANIK
|
$ 9.6 | 1.27 % | $ 141 M | Nasdaq Global Select Market,SPB | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
- | -9.72 % | $ 5.89 M | Nasdaq Capital Market | USA |
 |
Berkeley Lights
BLI
|
- | -7.31 % | $ 87 M | Nasdaq Global Select Market | USA |
 |
bluebird bio
BLUE
|
- | - | $ 546 M | Nasdaq Global Select Market,SPB | USA |
 |
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | USA |
 |
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | USA |
 |
Calithera Biosciences
CALA
|
- | -10.95 % | $ 876 K | Nasdaq Global Select Market | USA |
 |
Axon Enterprise
AXON
|
$ 584.81 | -1.07 % | $ 44.3 B | Nasdaq Global Select Market,SPB | USA |
 |
Cellectar Biosciences
CLRB
|
$ 2.53 | -8.33 % | $ 30.9 M | Nasdaq Capital Market | USA |
 |
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market | Israel |
 |
Aytu BioScience
AYTU
|
$ 2.44 | -3.56 % | $ 15.3 M | Nasdaq Capital Market | USA |
 |
AstraZeneca PLC
AZN
|
$ 92.79 | 0.37 % | $ 96.9 B | Nasdaq Global Select Market | Britain |
 |
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | USA |
 |
Catalyst Biosciences
CBIO
|
$ 12.33 | -0.29 % | $ 812 M | Nasdaq Capital Market | USA |
 |
Brickell Biotech
BBI
|
- | -5.38 % | $ 6.06 M | Nasdaq Capital Market | USA |
 |
Burford Capital Limited
BUR
|
$ 9.1 | 1.0 % | $ 1.48 B | NYSE | Britain |
 |
Celldex Therapeutics
CLDX
|
$ 26.29 | -2.01 % | $ 1.69 M | Nasdaq Global Select Market | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$ 11.07 | 2.45 % | $ 716 M | NYSE | USA |
 |
Biogen
BIIB
|
$ 176.45 | 0.07 % | $ 25.7 B | Nasdaq Global Select Market,SPB | USA |
|
Cerevel Therapeutics Holdings
CERE
|
- | - | $ 7.29 B | Nasdaq Capital Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.